<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79111">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02116946</url>
  </required_header>
  <id_info>
    <org_study_id>H13-00254</org_study_id>
    <nct_id>NCT02116946</nct_id>
  </id_info>
  <brief_title>Plasma Injections Plus Exercise for Patellar Tendinopathy</brief_title>
  <acronym>PHS</acronym>
  <official_title>Intratendinous Injections of Platelet Rich Plasma With or Without Leukocyte Enrichment for Patellar Tendinopathy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Orthopaedic Society for Sports Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rizzoli Orthopaedic Institute, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Olympic Training Center, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steadman-Hawkins Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled clinical trial to investigate the effectiveness, safety and
      tolerability of platelet-rich plasma (PRP) injections for treatment of patellar tendinopathy
      in adults 18-50 years of age.  Subjects will be randomly assigned to three parallel
      treatment groups:

        1. Leukocyte-rich PRP injection + exercise

        2. Leukocyte-poor PRP injection + exercise

        3. Saline injection + exercise (control) Primary endpoints are (1) the number (rate) and
           severity of adverse events as reported by both patients and study physicians during the
           first 12 weeks after initiation of treatment, (2) patient-rated tolerability of
           treatment; (3) the change in function (VISA score) and treatment success (global
           improvement scale) over six months of a post-injection exercise protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Efficacy</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number and frequency of adverse events will be assessed/reported weekly for the first 12 weeks and at the 6 month visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in function over time measured by VISA Score</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare change in function (VISA score) between participants randomized to the three treatment groups over six months, 1 year, and 2 years of a post-injection exercise protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of treatment success measured by Likert Global Improvement Scale</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare change in treatment success (Likert global improvement scale) between participants randomized to the three treatment groups over six months, 1 year, and 2 years of a post-injection exercise protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activity levels over time measured by Tegner Activity Score</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare change in activity levels (Tegner Activity Score) between participants randomized to the three groups over six months, 1 year, and 2 years of an exercise protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in activity-related pain over time measured by Pain Numeric Rating Scale</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare change in activity-related pain (Pain Numeric Rating Scale) between participants randomized to the three groups over six months, 1 year, and 2 years of an exercise protocol.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Patellar Tendinopathy</condition>
  <arm_group>
    <arm_group_label>Leukocyte-rich Platelet Rish Plasma + exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leukocyte-rich PRP injection and a 12 week exercise program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leukocyte-poor Platelet Rich Plasma + exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leukocyte-poor PRP injection and a 12 week exercise program.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + exercise</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline injection and a 12 week exercise program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich Plasma (PRP)</intervention_name>
    <description>Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.</description>
    <arm_group_label>Leukocyte-rich Platelet Rish Plasma + exercise</arm_group_label>
    <arm_group_label>Leukocyte-poor Platelet Rich Plasma + exercise</arm_group_label>
    <other_name>The device Angel cPRP System will be used to make  (Leukocyte-rich or -poor) PRP injections</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 and ≤ 50 years of age at Enrollment Visit

          -  Documentation of a clinical diagnosis of patellar tendinopathy, grade-IIIB Blazina
             stage,  confirmed on ultrasound

          -  Previously tried an exercise program of at least six weeks duration

          -  Fluent in official language of study site

          -  Written informed consent obtained from subject

          -  Normal values on screening laboratory panels (CBC, PT, PTT, INR, serum creatine, ALT,
             ALP, AST, bilirubin, albumin)

        Exclusion Criteria:

          -  For women of child-bearing potential, positive pregnancy test at enrollment visit

          -  Major surgery in the past three months

          -  Surgery on the symptomatic knee

          -  Bleeding disorder

          -  Systemic inflammatory disease

          -  Arthritis or degenerative knee condition

          -  Recent fluoroquinolone use

          -  Subjects who have any requirement for the use of systemic steroids or
             immunosuppressants

          -  Subjects who are known to be HIV positive

          -  Uncooperative patient, or patients who are incapable of following directions or who
             are predictably unwilling to return for follow-up examinations

          -  Presence of a condition or abnormality that in the opinion of the Investigator would
             compromise the safety of the patient or the quality of the data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Scott, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Steadman Clinic</name>
      <address>
        <city>Vail</city>
        <state>Colorado</state>
        <zip>81657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert LaPrade, MD, PhD</last_name>
      <phone>970-479-5881</phone>
      <email>rlaprade@thesteadmanclinic.com</email>
    </contact>
    <investigator>
      <last_name>Robert Laprade, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Harmon, MD</last_name>
      <phone>206-520-5000</phone>
      <email>kharmon@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Harmon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Britich Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Scott, PhD</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>21810</phone_ext>
      <email>alex.scott@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Alex Scott, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizaveta Kon, MD</last_name>
      <phone>39-051-6366567</phone>
      <email>e.kon@biomec.ior.it</email>
    </contact>
    <investigator>
      <last_name>Elizaveta Kon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo Sports Trauma Research Center</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Engebretsen, MD, PhD</last_name>
      <phone>47 22 85 50 50</phone>
      <email>lars.engebretsen@medisin.uio.no</email>
    </contact>
    <investigator>
      <last_name>Lars Engebretsen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roald Bahr, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Lian OB, Engebretsen L, Bahr R. Prevalence of jumper's knee among elite athletes from different sports: a cross-sectional study. Am J Sports Med. 2005 Apr;33(4):561-7. Epub 2005 Feb 8.</citation>
    <PMID>15722279</PMID>
  </reference>
  <reference>
    <citation>Lian O, Engebretsen L, Ovrebø RV, Bahr R. Characteristics of the leg extensors in male volleyball players with jumper's knee. Am J Sports Med. 1996 May-Jun;24(3):380-5.</citation>
    <PMID>8734892</PMID>
  </reference>
  <reference>
    <citation>Engebretsen, L, K Steffen, J Alsousou et al. IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med 2010; 44: (15) 1072-81.</citation>
  </reference>
  <reference>
    <citation>Bahr R, Fossan B, Løken S, Engebretsen L. Surgical treatment compared with eccentric training for patellar tendinopathy (Jumper's Knee). A randomized, controlled trial. J Bone Joint Surg Am. 2006 Aug;88(8):1689-98.</citation>
    <PMID>16882889</PMID>
  </reference>
  <reference>
    <citation>Warden SJ, Metcalf BR, Kiss ZS, Cook JL, Purdam CR, Bennell KL, Crossley KM. Low-intensity pulsed ultrasound for chronic patellar tendinopathy: a randomized, double-blind, placebo-controlled trial. Rheumatology (Oxford). 2008 Apr;47(4):467-71. doi: 10.1093/rheumatology/kem384. Epub 2008 Feb 12.</citation>
    <PMID>18270224</PMID>
  </reference>
  <reference>
    <citation>Kongsgaard M, Kovanen V, Aagaard P, Doessing S, Hansen P, Laursen AH, Kaldau NC, Kjaer M, Magnusson SP. Corticosteroid injections, eccentric decline squat training and heavy slow resistance training in patellar tendinopathy. Scand J Med Sci Sports. 2009 Dec;19(6):790-802. doi: 10.1111/j.1600-0838.2009.00949.x. Epub 2009 May 28.</citation>
    <PMID>19793213</PMID>
  </reference>
  <reference>
    <citation>Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet-rich plasma for the treatment of refractory jumper's knee. Int Orthop. 2010 Aug;34(6):909-15. doi: 10.1007/s00264-009-0845-7. Epub 2009 Jul 31.</citation>
    <PMID>19641918</PMID>
  </reference>
  <reference>
    <citation>Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, Bondi A, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury. 2009 Jun;40(6):598-603. Epub 2009 Apr 19.</citation>
    <PMID>19380129</PMID>
  </reference>
  <reference>
    <citation>Banfi G, Corsi MM, Volpi P. Could platelet rich plasma have effects on systemic circulating growth factors and cytokine release in orthopaedic applications? Br J Sports Med. 2006 Oct;40(10):816. Epub 2006 Aug 18.</citation>
    <PMID>16920768</PMID>
  </reference>
  <reference>
    <citation>Thanasas, C, G Papadimitriou, C Charalambidis et al. Platelet-rich plasma versus autologous whole blood for the treatment of chronic lateral elbow epicondylitis: a randomized controlled clinical trial. Am J Sports Med 2011; 39: (10) 2130-4.</citation>
  </reference>
  <reference>
    <citation>Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J; IMMPACT. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005 Jan;113(1-2):9-19. Review.</citation>
    <PMID>15621359</PMID>
  </reference>
  <reference>
    <citation>Briggs KK, Steadman JR, Hay CJ, Hines SL. Lysholm score and Tegner activity level in individuals with normal knees. Am J Sports Med. 2009 May;37(5):898-901. doi: 10.1177/0363546508330149. Epub 2009 Mar 23.</citation>
    <PMID>19307332</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
